Comparison of the effect of fluocinolone drug with oral atorvastatin on the treatment of patients with vitiligo

Comparison of the effect of fluocinolone drug with oral atorvastatin with fluocinolone alone on the treatment of patients with vitiligo

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151228025732N64

Enrollment

Registered

2021-02-12

Start date

2021-01-20

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo. Vitiligo

Interventions

Intervention 1: Control group: Patients receive routine treatment (fluocinolone ointment %0.025 - Darupakhsh Company) topical for 12 weeks and twice a day. Intervention 2: Intervention group: Patients

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age 20-60 years Infection of less than 20% of the body surface with vitiligo Vitiligo over the past year

Exclusion criteria

Exclusion criteria: Pregnant or lactating woman With systemic and metabolic diseases (diabetes, thyroid diseases, etc.)

Design outcomes

Primary

Measure	Time frame
The severity of the disease. Timepoint: Before intervention, 1 and 2 months after intervention. Method of measurement: Scoring using the vitiligo area severity index (VASI) and clinical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Azizzadeh

Semnan University of Medical Sciences

are20935@gmail.com+98 23 3345 1336

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026